Houston-based FibroBiologics, Inc. (Nasdaq: FBLG) announced the closing of a private placement on June 29, 2026, raising USD 3.0 million in upfront gross proceeds with the potential for up to USD 9.0 million in total capital if accompanying warrants are exercised in full. For a clinical-stage company that has executed multiple small financings over the past eight months to sustain operations, this transaction extends near-term working capital while preserving optionality for additional proceeds contingent on stockholder approval.
The offering comprised 4,081,633 shares of common stock, or pre-funded warrants in lieu thereof, priced at USD 0.735 per share. Two warrant series accompanied the shares: Series A warrants exercisable for up to 4,081,633 shares and short-term Series B warrants covering the same number of shares, both at an exercise price of USD 0.735 per share. Neither warrant series is exercisable until stockholder approval of the underlying share issuances is obtained. The Series A warrants expire five years from the later of the stockholder approval date and the effective date of a resale registration statement FibroBiologics has agreed to file; the Series B warrants carry an 18-month term from the same reference date. Full cash exercise of both series would generate approximately USD 6.0 million in additional proceeds, though no assurance exists that any warrants will be exercised. H.C. Wainwright & Co. acted as exclusive placement agent. Investor identities were not disclosed. Proceeds are designated for working capital and general corporate purposes.
FibroBiologics is a clinical-stage biotechnology company developing therapeutics derived from fibroblast cells and fibroblast-derived materials, targeting chronic diseases across wound healing, multiple sclerosis, intervertebral disc degeneration, psoriasis, and oncology. The company's most advanced program is a Phase I/II diabetic foot ulcer trial for its lead candidate CYWC628, a fibroblast cell therapy designed to promote tissue regeneration in chronic wounds. IND-enabling studies are also underway for a psoriasis program designated CYPS317. Neither program has reported clinical data to date.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/
Spot something wrong? Report an issue with this article